Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 10/20 | 0.51 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 5/20 | 0.31 |
| ▸ | WNT1 | P04628 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.30 |
| ▸ | CHUK | O15111 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20306070 | 0.95 | TTBK1 (0.57) | TTBK1CAMK2DMAP3K14WNT1GSK3B | |
| SCHEMBL16610201 | 0.90 | TTBK1 (0.49) | TTBK1CAMK2DMAP3K14WNT1GSK3B | |
| SCHEMBL16610214 | 0.88 | TTBK1 (0.60) | TTBK1MAP3K14WNT1GSK3BDYRK1A | |
| SCHEMBL18080750 | 0.87 | TTBK1 (0.70) | TTBK1CAMK2DMAP3K14TTBK2 | |
| SCHEMBL16610271 | 0.84 | TTBK1 (0.63) | TTBK1MAP3K14CHUK | |
| SCHEMBL16610345 | 0.83 | TTBK1 (0.52) | TTBK1MAP3K14TTBK2 | |
| SCHEMBL16610281 | 0.82 | TTBK1 (0.36) | TTBK1CAMK2DWNT1GSK3BDYRK1A | |
| SCHEMBL21880207 | 0.81 | TTBK1 (0.50) | TTBK1MAP3K14TTBK2 | |
| SCHEMBL20306071 | 0.81 | TTBK1 (0.79) | TTBK1CAMK2DMAP3K14TTBK2CHUK | |
| SCHEMBL16610212 | 0.81 | TTBK1 (0.49) | TTBK1MAP3K14TTBK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160257679-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257679-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K12 | TTBK1 558/4885CAMK2D 406/4885MAP3K14 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.